- Home
- SHOO vs BEAM Comparison
SHOO vs BEAM Comparison
Compare SHOO & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOO
- BEAM
- Stock Information
- Founded
- SHOO 1990
- BEAM 2017
- Country
- SHOO United States
- BEAM United States
- Employees
- SHOO N/A
- BEAM N/A
- Industry
- SHOO Shoe Manufacturing
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SHOO Consumer Discretionary
- BEAM Health Care
- Exchange
- SHOO Nasdaq
- BEAM Nasdaq
- Market Cap
- SHOO 2.8B
- BEAM 2.3B
- IPO Year
- SHOO 1993
- BEAM 2020
- Fundamental
- Price
- SHOO $27.42
- BEAM $17.64
- Analyst Decision
- SHOO Hold
- BEAM Strong Buy
- Analyst Count
- SHOO 6
- BEAM 11
- Target Price
- SHOO $40.20
- BEAM $50.50
- AVG Volume (30 Days)
- SHOO 1.8M
- BEAM 2.7M
- Earning Date
- SHOO 04-30-2025
- BEAM 05-06-2025
- Dividend Yield
- SHOO 3.06%
- BEAM N/A
- EPS Growth
- SHOO 2.17
- BEAM N/A
- EPS
- SHOO 2.35
- BEAM N/A
- Revenue
- SHOO $2,282,927,000.00
- BEAM $63,518,000.00
- Revenue This Year
- SHOO $20.37
- BEAM N/A
- Revenue Next Year
- SHOO $8.99
- BEAM $6.32
- P/E Ratio
- SHOO $11.67
- BEAM N/A
- Revenue Growth
- SHOO 15.21
- BEAM N/A
- 52 Week Low
- SHOO $24.56
- BEAM $17.55
- 52 Week High
- SHOO $50.01
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- SHOO 39.88
- BEAM 27.84
- Support Level
- SHOO $25.92
- BEAM $21.60
- Resistance Level
- SHOO $27.51
- BEAM $22.97
- Average True Range (ATR)
- SHOO 0.91
- BEAM 1.71
- MACD
- SHOO 0.58
- BEAM -0.53
- Stochastic Oscillator
- SHOO 96.30
- BEAM 0.79
About SHOO Steven Madden Ltd.
Steven Madden Ltd designs and sells brand-name and private-label footwear and accessories. Its products are geared toward fashion-conscious adults and children. The company sells its products through department stores and other retailers as well as its own stores and websites. The company's revenue comes from its operating segments: Wholesale Footwear, Wholesale Accessories or Apparel, Direct-to-Consumer, and Licensing. The wholesale footwear segment accounts for the majority of revenue.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.